Skip to main content

Table 1 Patients groups characteristics

From: Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients

 

No platinum reduction or delays

Platinum reduction only

Delays only

Both Platinum reduction and delays

(N = 15)

(N = 11)

(N = 12)

(N = 44)

Age, mean (range)

46.6 (22–67)

52.0 (42–65)

60.8 (42–82)

59.7 (40–82)

BMI, mean (range)

24.9 (16.1–46.1)

25.1 (18.2–33.7)

26.5 (19.5–39.5)

26.9 (16.7–38.2)

(kg/m2)

Histology

    

Serous

13 (86.6%)

11 (100%)

10 (83.4%)

32 (72.7%)

Mucinous

1 (6.7%)

0 (0%)

1 (8.3%)

4 (9.1%)

Endometrioid

0 (0%)

0 (0%)

1 (8.3%)

1 (2.3%)

Clear cell

0 (0%)

0 (0%)

0 (0%)

2 (4.5%)

Mixed

1 (6.7%)

0 (0%)

0 (0%)

5 (11.4)

Tumor grade

    

Grade 1

0 (0%)

1 (9.1%)

1 (8.3%)

6 (13.6%)

Grade 2

11 (73.3%)

8 (72.7%)

9 (75.0%)

24 (54.6%)

Grade 3

4 (26.7%)

2 (18.2%)

2 (16.7%)

14 (31.8%)

  1. (N = 82).